By Scott Kanowsky
Investing.com -- Shares in GlaxoSmithKline (LON: GSK ) moved higher on Wednesday after the drugmaker lifted its full-year earnings and sales outlook following better-than-expected third-quarter results.
The U.K.-based group now expects adjusted operating profit to increase between 15%-17% in 2022, while revenue, excluding pandemic-related sales, is seen rising by 8%-10%.
It had previously guided for an income leap of 13%-15% on revenue growth of 6%-8%.
The move comes after GSK posted turnover of £7.83 billion in the third quarter - an expansion of 9% compared to the corresponding period last year - driven in part by record demand for its Shingrix shingles vaccine.
GSK's specialty medicines division also reported quarterly sales of £2.75 billion, a 24% year-on-year jump, thanks to strong performance of its COVID-19 medicine Xevudy.
Adjusted operating profit during the three months to September 30 climbed by 4% to £2.6 billion.
"We are again raising our full-year guidance and expect good momentum in 2023, further strengthening our confidence in our performance outlooks," said chief executive officer Emma Walmsley in a statement.
She added that the firm is making "good progress" in strengthening its drug pipeline and will continue to "invest in targeted business development."
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.